Opinion|Videos|January 8, 2025
Emerging Maintenance Strategies in Advanced/Metastatic Disease: Insights on Combination Therapies and Overcoming PARP Inhibitor Resistance
Author(s)Thomas J. Herzog, MD, John Chan, MD
Panelists discuss PARP inhibitor resistance in ovarian cancer and explore strategies to overcome this challenge, including findings from the PRESERVE-004 trial evaluating gotistobart plus pembrolizumab, along with other potential treatment options. Additionally, they review insights from the SOPRANO trial regarding the management of oligometastases or oligoprogression in ovarian cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr Chan to ask Dr Herzog: Please comment on PARP inhibitor resistance. Are there promising strategies to overcome this challenge?
- PRESERVE-004: gotistobart plus pembrolizumab (
Barlin JN, et al. ESMO 2024. LBA32 ) - Others?
Dr Herzog to ask Dr Chan: What insights can be drawn from the SOPRANO trial findings regarding the management of oligometastases or oligoprogression in ovarian cancer? (
Advertisement
Related to this article
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
The HER2-directed ADC produced confirmed responses across both biomarker-defined cohorts of advanced salivary gland carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
4
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
5